Skip to main content

Turn Therapeutics Inc.

corporate_fare Company Profile

Turn Therapeutics Inc.

TTRX·NASDAQ·Life Sciences·CIK 0002023016

Turn Therapeutics develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases. The company's primary focus is its lead program, GX-03, which is being studied for moderate-to-severe eczema. This research is based on preclinical evidence showing it can inhibit cytokines and reduce eczema severity, alongside a favorable real-world tolerability record from its prior use in cleared medical device indications. GX-03 is currently in an ongoing, randomized, double-blind, vehicle-controlled clinical study for moderate-to-severe eczema, with an interim assessment planned at approximately 50% trial completion. Topline results are expected mid-2026. In addition to eczema, GX-03 is being developed for onychomycosis, supported by in-vivo data demonstrating nail penetration and antifungal activity. The company's historical medical device portfolio, including K183681, K160872, and K171191, provides background tolerability and feasibility experience with the formula. K183681 has been licensed to Medline under a license and supply agreement. Turn Therapeutics is seeking new drug approvals for the GX-03 formula, which includes polyhexanide ("PHMB"), as a treatment for both eczema and onychomycosis. PHMB is a well-characterized polymer with strong antimicrobial, anti-inflammatory, and immunomodulating properties, and an established safety profile. The company also conducts exploratory work on a thermostable intranasal vaccine platform, but this is not part of its primary dermatology development path.

Turn Therapeutics Inc. (NASDAQ:TTRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for TTRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for TTRX spans 424B3, 8-K, S-3, 10-Q.

Recent high-impact activity:

  • Turn Therapeutics Registers 25.4M Shares for Resale Under $85M GEM Equity Line
  • Turn Therapeutics Posts New GX-03 Subgroup Data: 61.5% vs 8.3% vIGA Success at Week 4
  • Turn Therapeutics Files $150M Shelf and Launches $50M TD Cowen ATM
  • Turn Therapeutics Registers 25.4M Shares for Resale, ~83% of Outstanding, in S-3
  • Turn Therapeutics 10-Q: $13.1M Nine-Month Loss, Going Concern, $10.4M Cash Into Q3 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$3.19M
Diluted EPS
-$0.12
Op. Cash Flow
-$2.56M
Operating Income
-$5.86M
Cash & Equivalents
$4.03M
Debt / Equity
0.00×
Shares Outstanding
29.45M sh
Source: 10-K · filed 2026-03-31 · accession 0001213900-26-037505

Short Interest & Short Volume

5.87 days to cover

FINRA reported short interest of 530,526 shares in TTRX as of the October 30, 2026 settlement, a 23.0% increase from the prior period — about 5.9 days to cover at its recent average daily volume. On November 20, 2026, 55.1% of TTRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)530,526 shares as of October 30, 2026
Change vs prior period▲ 23.0%
Days to cover5.87 at avg daily volume of 90,436
Daily short volume (FINRA facilities)55.1% of 43,346 shares on November 20, 2026
5-day average short volume52.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for TTRX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.

1 recent capital raise2 shelf registrations

ATM Prospectus Filed, No Sales Yet · Dilution Math Quantified

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$8 -1.14% today
52-week range · as of 2026-11-16 $2.57 – $16.45
Market cap
$247.49M
Volume
82.8K (0.9× avg)
3-mo avg 95K
Live data · 2026-11-21 23:29 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TTRX - Latest Insights

TTRX
Nov 16, 2026, 4:23 PM EST
Filing Type: 424B3
Importance Score:
7
Price at Filing: $8.55
Real-time Price: $8.00 info
Change: -$0.5475 (-6%) info
Market Cap: $247.486M info
TTRX
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.79
Real-time Price: $8.00 info
Change: -$1.79 (-18%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 8:05 AM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 8:00 AM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 7:02 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 05, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.80
Real-time Price: $8.00 info
Change: -$1.80 (-18%) info
Market Cap: $247.486M info
TTRX
Oct 06, 2026, 7:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.64
Real-time Price: $8.00 info
Change: -$3.64 (-31%) info
Market Cap: $247.486M info
TTRX
Aug 12, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.54
Real-time Price: $8.00 info
Change: -$2.54 (-24%) info
Market Cap: $247.486M info
TTRX
Aug 12, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.54
Real-time Price: $8.00 info
Change: -$2.54 (-24%) info
Market Cap: $247.486M info
TTRX
Aug 12, 2026, 4:30 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $10.54
Real-time Price: $8.00 info
Change: -$2.54 (-24%) info
Market Cap: $247.486M info
TTRX
Jul 28, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.54
Real-time Price: $8.00 info
Change: -$0.5375 (-6%) info
Market Cap: $247.486M info
TTRX
Jul 07, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.99
Real-time Price: $8.00 info
Change: +$0.0125 (+0.16%) info
Market Cap: $247.486M info
TTRX
Jul 06, 2026, 5:28 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.71
Real-time Price: $8.00 info
Change: +$0.2925 (+4%) info
Market Cap: $247.486M info
TTRX
Jun 03, 2026, 6:12 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.40
Real-time Price: $8.00 info
Change: +$1.60 (+25%) info
Market Cap: $247.486M info
TTRX
Jun 01, 2026, 2:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $6.56
Real-time Price: $8.00 info
Change: +$1.45 (+22%) info
Market Cap: $247.486M info
TTRX
Jun 01, 2026, 8:53 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $5.67
Real-time Price: $8.00 info
Change: +$2.33 (+41%) info
Market Cap: $247.486M info
TTRX
Jun 01, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.01
Real-time Price: $8.00 info
Change: +$2.99 (+60%) info
Market Cap: $247.486M info
TTRX
May 27, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.37
Real-time Price: $8.00 info
Change: +$2.63 (+49%) info
Market Cap: $247.486M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets